Press Releases Precigen, Inc.

Equities

PGEN

US74017N1054

Real-time Estimate Cboe BZX Other stock markets 02:52:41 2024-05-06 pm EDT			5-day change	1st Jan Change
1.435 ^USD	+1.06%		+2.86%	+7.47%

Apr. 24	Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy	CI
Mar. 25	North American Morning Briefing : Tech in Focus on -2-	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting	Apr. 25	AQ
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th	Mar. 28	PR
Precigen Reports Full Year 2023 Financial Results and Business Updates	Mar. 20	AQ
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis	Mar. 12	PR
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th	Mar. 05	PR
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	PR
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	Jan. 16	PR
Precigen Highlights Pipeline Updates to be presented at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 09	AQ
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 18	PR
Precigen to Participate in the JMP Securities Hematology and Oncology Summit	Nov. 29	PR
Precigen to Participate in the Stifel 2023 Healthcare Conference	Nov. 07	PR
Precigen to Participate in Upcoming Leading Investor and Industry Conferences	23-09-19	PR
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025	23-08-10	AQ
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval	23-08-09	PR
Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th	23-08-03	PR
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis	23-06-21	AQ
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis	23-06-20	PR
PRECIGEN, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	23-06-09	AQ
Precigen Reports First Quarter 2023 Financial Results and Business Updates	23-05-11	AQ
PRECIGEN, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Precigen, Inc.

Equities

PGEN

US74017N1054

Press Releases

Filters